Japanese Pharma Sea Change: U.S. Development Takes Focus Over Licensing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Japanese pharma firms are changing the long-standing practice of out-licensing products in the U.S., with maturing U.S. operations now directly developing more than a dozen drugs in or near Phase III.